

Paxman publishes newsletter on that a sustained Medicare payment rate for scalp cooling is proposed for 2023

Today, Paxman publishes the August issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights that Centers for Medicare & Medicaid Services (CMS) in the United States has proposed Medicare payment rates for hospital outpatient and Ambulatory Surgical Center (ASC) services for the calendar year 2023. If the proposed rule is finalized without changes, this would mean that scalp cooling treatments billed with the CPT code 0662T will continue to have a payment rate of 1,850.50 USD. The final rule will be issued in early November.

The newsletter also includes information on that Paxman Scalp Cooling is available at 6 of the 10 top U.S. cancer hospitals, orders from locations in eight states in the US, several customers in the UK as well as from France, Schweiz and Singapore, the launch of Paxman's PSCS system in Japan and that the company's distributors in Colombia and Singapore received market clearance for Paxman Scalp Cooling from each country's respective regulatory agency in charge of medical devices.

To read the newsletter and subscribe for upcoming issues, follow this link:

<https://bit.ly/paxaug22en>

Paxman's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on Paxman's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

For more information, please contact:

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,400 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Paxman publishes newsletter on that a sustained Medicare payment rate for scalp cooling is proposed for 2023](#)